Journal Logo

Articles by N. Daver

RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY: PF205

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3:54-55, June 2019.

A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES: PF291

Dinardo, C.; Takahashi, K.; Kadia, T.; More

HemaSphere. 3:97, June 2019.

PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML): PF673

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3:289-290, June 2019.

EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS): PS1064

Alfayez, M.; Kantarjian, H.; Ravandi, F.; More

HemaSphere. 3:481-482, June 2019.

SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.: S1615

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3:745, June 2019.

IMPACT OF CD33 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH DECITABINE PLUS GEMTUZUMAB OZOGAMICIN: PB1722

Short, N.; Richard-Carpentier, G.; Kanagal-Shamanna, R.; More

HemaSphere. 3:791-792, June 2019.